CUMYL-BC-HPMEGACLONE-221

Cumyl-BC-HpMeGaClone-221 (Cumyl-BC[2.2.1]HpMeGaClone, SGT-271) is a gamma-carboline derivative which is a synthetic cannabinoid that has been sold as a designer drug. It was first identified in Germany in September 2020.[1]

Cumyl-BC-HpMeGaClone-221
Identifiers
  • 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-[(bicyclo[2.2.1]cyclohept-2-yl)methyl]-1H-pyrido[4,3-b]indol-1-one
Chemical and physical data
FormulaC28H30N2O
Molar mass410.561 g·mol−1
3D model (JSmol)
  • CC(C)(c1ccccc1)N1C=Cc2n(CC3CC4CCC3C4)c3ccccc3c2C1=O
  • InChI=1S/C28H30N2O/c1-28(2,22-8-4-3-5-9-22)30-15-14-25-26(27(30)31)23-10-6-7-11-24(23)29(25)18-21-17-19-12-13-20(21)16-19/h3-11,14-15,19-21H,12-13,16-18H2,1-2H3
  • Key:VFBNNQOHBYEVLU-UHFFFAOYSA-N

See also


References
  1. European Monitoring Center for Drugs and Drug Addiction (December 2020). "New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System" (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. Cite journal requires |journal= (help)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.